The Second Xiaoxiang Forum of Medical Oncology, the Sixth Yuelu Lymphoma Forum, and the 2025 Annual Conference of the Lymphoma Professional Committee of the Hunan Anti-Cancer Association came to a successful conclusion in Changsha from November 14 to 16, 2025. The conference was hosted by the Hunan Anti-Cancer Association and organized by the Hunan Cancer Hospital and the Lymphoma Professional Committee of the Hunan Anti-Cancer Association, bringing together a number of renowned experts in hematologic oncology from across the country. The forum presented the latest advances in the diagnosis and treatment of lymphoma, multiple myeloma, leukemia, and other hematologic malignancies, and engaged in in-depth discussions on difficult issues and hot topics encountered in the diagnosis and treatment of various diseases.
Professor Zhou Hui, Conference Chairman, Director of the Hunan Lymphoma Diagnosis and Treatment Center, Director of the Hunan Engineering Research Center for Precision Diagnosis and Treatment of Lymphoma, and Chairman-Elect of the Medical Oncology Professional Committee of the Hunan Medical Association, stated in his opening address that over the past year, the alliance has achieved significant results in enhancing the comprehensive diagnosis and treatment capabilities for hematologic malignancies in the region, particularly in the treatment of various lymphoma subtypes. He emphasized that, given the current wave of novel drugs for hematologic diseases, continuously advancing individualized and optimized treatment strategies is of great importance for improving long-term patient outcomes and quality of life.
The conference brought together leading experts to share domestic and international treatment advances.
Several leading domestic experts in the field of hematology delivered insightful presentations on a number of hot topics, including "Standardized Diagnosis and Treatment of Follicular Lymphoma and Recent Advances," "Advances in Immunotherapy for Multiple Myeloma," "Research Progress on CAR-T Combined with Autologous Transplantation for High-Risk Diffuse Large B-Cell Lymphoma," "Comprehensive Management of CIN and FN Induced by Hematologic Tumor Drug Therapy," and "Current Status and Future Prospects of Advanced Therapies and Innovative Drugs for Hematologic and Lymphatic System Diseases." These presentations provided fresh perspectives for clinical practice.
Lenalidomide Gains Academic Recognition, Its Clinical Value Stands Out
During the conference, lenalidomide, as a first-line drug recommended by treatment guidelines for multiple myeloma and follicular lymphoma, was hailed by multiple experts as the "cornerstone choice" for the treatment of these two diseases. Relevant clinical study data further confirmed its efficacy and safety: durvalumab combined with lenalidomide for the treatment of refractory/advanced cutaneous T-cell lymphoma achieved an objective response rate of 75% and a 1-year progression-free survival rate of 73%, demonstrating significant superiority over monotherapy.
Mosun + Len for the treatment of treatment-naïve follicular lymphoma (FL): Lenalidomide (Len), as a potent immunomodulatory agent, exhibits additive and synergistic effects with anti-CD20 antibodies in lymphoma models. The Mosun combined with lenalidomide regimen has shown a manageable safety profile and promising activity in both treatment-naïve and relapsed/refractory follicular lymphoma.
Furthermore, multiple clinical studies have incorporated lenalidomide into core treatment regimens, including orelabrutinib combined with lenalidomide and rituximab for the treatment of mantle cell lymphoma, and lenalidomide combined with the CHOP regimen for specific genetic subtypes of peripheral T-cell lymphoma. The synergistic effects of lenalidomide in combination therapies have garnered widespread attention.
Sino Universal Pharma Gathers Cutting-Edge Advances and Fulfills Its Mission
During the conference, our company's representatives engaged in in-depth exchanges with participating experts on topics such as new trends in the treatment of multiple myeloma and lymphoma, real-world studies, and the clinical application of innovative drugs. We deeply felt the urgent clinical need for treatment options that offer better efficacy, higher safety, and improved quality of life.
Le'an Jirui® Lenalidomide Capsules, as a product selected in the ninth round of national volume-based procurement, have also been included in the Hunan Provincial Medical Insurance "Dual Channel" Single-Payment Management Drug Catalog, providing patients with multiple myeloma and lymphoma in Hunan Province with a high-quality, affordable treatment option.
This conference was not only an academic feast in the field of hematologic oncology but also a new starting point for building consensus and deepening collaboration. Through participation in this conference, Sinopharm Central Health not only gained insights into cutting-edge academic developments but also further strengthened its determination to devote itself to the cause of hematologic disease prevention and treatment. Moving forward, we will continue to uphold our mission of "Bringing global good medicines, serving a healthy China," strengthen cooperation with the academic and clinical communities, and promote access to high-quality, affordable drugs, including lenalidomide, to light up the hope of life for more patients.
